Learning lessons from Relenza, Biota must obtain the manufacturing and selling of Lani in order to succeed in frofiting from Lani.
Relenza is also excellent drug, but GSK does not want to promote it. If Lani is given away like Relenza, the same would probably happen to it. I think those big pharms just want to cap the growth of BTA in their best intersts. remember BTA still have other excellent piplelines?
jsut my thoughts.
- Forums
- ASX - By Stock
- BTA
- live webcast on grant